Product comprising a heterotrimeric g protein signal transduction inhibitor associated with anti-hypertensive agent for therapeutic use in the treatment of arterial hypertension
CA 2395955 A1 · Owner: Societe De Conseils De Recherches Et D'Applications Scientifiques (S.C.R · Inventors: Teillot, Marc; Prevost, Gregoire
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The invention concerns a product comprising at least an inhibitor of heterotrimeric G protein signal transduction associated with at least another anti-hypertensive agent in particular calcium channel blockers and conversion enzyme inhibitors for simultaneous, separate or prolonged therapeutic use in the treatment of hypertension.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed January 5, 2001. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended January 5, 2021.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by January 5, 2023.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.